Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Travere Therapeutics, Inc.TVTX · Entity 1562 | SVP, CHIEF ACCOUNTING OFFICER | September 15, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Travere Therapeutics, Inc.
Report date September 15, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,353 |
Ending reported balance
After 2026-09-15 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 2,500 · Balance 44,853 Row 2 · 2026-09-15 · Exercise / conversion · Acquired 1,250 · Balance 46,103 Row 3 · 2026-09-15 · Exercise / conversion · Acquired 1,625 · Balance 47,728 Row 4 · 2026-09-15 · Sale · Disposed 4,275 · Balance 43,453 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2: The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 5 · 2026-09-15 · Sale · Disposed 800 · Balance 42,653 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3: The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 6 · 2026-09-15 · Sale · Disposed 300 · Balance 42,353 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F4: The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.50 · Expires 2032-01-31 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-15 · Exercise / conversion · Disposed 2,500 · Balance 0 F5: The stock option is fully vested and exercisable. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.40 · Expires 2033-01-31 | Direct | 3,750 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 1,250 · Balance 3,750 F6: One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.46 · Expires 2035-01-31 | Direct | 17,875 |
Reported balance
After 2026-09-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-15 · Exercise / conversion · Disposed 1,625 · Balance 17,875 F7: One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2: The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4: The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5: The stock option is fully vested and exercisable.
F6: One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
F7: One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 18, 2026 01:29 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 1,625 | $0.00 Strike: $20.46 | $0.00 |
DisclosureSEC source: 0001882909-26-000004 · form4-09182026_010916.xml · derivative · entry 9 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,875 Underlying: Common Stock · 1,625 shares Expires 2035-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:29 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 1,250 | $0.00 Strike: $22.40 | $0.00 |
DisclosureSEC source: 0001882909-26-000004 · form4-09182026_010916.xml · derivative · entry 8 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1,250 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:29 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 2,500 | $0.00 Strike: $27.50 | $0.00 |
DisclosureSEC source: 0001882909-26-000004 · form4-09182026_010916.xml · derivative · entry 7 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:29 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 300 | $63.66 | $19,098.99 |
DisclosureSEC source: 0001882909-26-000004 · form4-09182026_010916.xml · nonDerivative · entry 6 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,353 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F4 · price: The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:29 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 800 | $62.85 | $50,278.48 |
DisclosureSEC source: 0001882909-26-000004 · form4-09182026_010916.xml · nonDerivative · entry 5 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,653 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3 · price: The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:29 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 4,275 | $62.14 | $265,627.13 |
DisclosureSEC source: 0001882909-26-000004 · form4-09182026_010916.xml · nonDerivative · entry 4 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,453 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2 · price: The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:29 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 1,625 | $20.46 | $33,247.50 |
DisclosureSEC source: 0001882909-26-000004 · form4-09182026_010916.xml · nonDerivative · entry 3 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:29 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 1,250 | $22.40 | $28,000.00 |
DisclosureSEC source: 0001882909-26-000004 · form4-09182026_010916.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:29 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 2,500 | $27.50 | $68,750.00 |
DisclosureSEC source: 0001882909-26-000004 · form4-09182026_010916.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 6,500 | $0.00 Strike: $20.46 | $0.00 |
DisclosureSEC source: 0001882909-26-000003 · form4-04162026_040403.xml · derivative · entry 7 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 6,500 shares Expires 2035-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 6,250 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001882909-26-000003 · form4-04162026_040403.xml · derivative · entry 6 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2034-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 2,500 | $0.00 Strike: $22.40 | $0.00 |
DisclosureSEC source: 0001882909-26-000003 · form4-04162026_040403.xml · derivative · entry 5 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 21,977 | $41.07 | $902,595.39 |
DisclosureSEC source: 0001882909-26-000003 · form4-04162026_040403.xml · nonDerivative · entry 4 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,353 F1 · kind: This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 6,500 | $20.46 | $132,990.00 |
DisclosureSEC source: 0001882909-26-000003 · form4-04162026_040403.xml · nonDerivative · entry 3 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 6,250 | $8.93 | $55,812.50 |
DisclosureSEC source: 0001882909-26-000003 · form4-04162026_040403.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 2,500 | $22.40 | $56,000.00 |
DisclosureSEC source: 0001882909-26-000003 · form4-04162026_040403.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 02:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 4,333 | $32.12 | $139,175.96 |
DisclosureSEC source: 0001882909-26-000001 · form4-02032026_090201.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,080 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 31, 2026 Filed Feb 4, 2026 02:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 20,160 | $0.00 Strike: $33.10 | $0.00 |
DisclosureSEC source: 0001882909-26-000001 · form4-02032026_090201.xml · derivative · entry 3 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,160 Underlying: Common Stock · 20,160 shares Expires 2036-01-31 F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 31, 2026 Filed Feb 4, 2026 02:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 15,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001882909-26-000001 · form4-02032026_090201.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,413 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. Read SEC document |
| December 24, 2025 Filed Dec 30, 2025 01:59 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 7,402 | $40.00 | $296,080.00 |
DisclosureSEC source: 0001882909-25-000008 · form4-12302025_011208.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,233 F1 · kind: This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:23 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,910 | $36.00 | $104,760.00 |
DisclosureSEC source: 0001882909-25-000006 · form4-12162025_091205.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,635 F1 · kind: This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 6,250 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001882909-25-000004 · form4-11062025_041101.xml · derivative · entry 11 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires 2034-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $22.40 | $0.00 |
DisclosureSEC source: 0001882909-25-000004 · form4-11062025_041101.xml · derivative · entry 10 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 12,500 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.50 | $0.00 |
DisclosureSEC source: 0001882909-25-000004 · form4-11062025_041101.xml · derivative · entry 9 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 15,000 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2022, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 17,500 | $0.00 Strike: $26.88 | $0.00 |
DisclosureSEC source: 0001882909-25-000004 · form4-11062025_041101.xml · derivative · entry 8 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2031-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001882909-25-000004 · form4-11062025_041101.xml · derivative · entry 7 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 67,115 | $36.00 | $2,416,140.00 |
DisclosureSEC source: 0001882909-25-000004 · form4-11062025_041101.xml · nonDerivative · entry 6 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,545 F1 · kind: This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 6,250 | $8.93 | $55,812.50 |
DisclosureSEC source: 0001882909-25-000004 · form4-11062025_041101.xml · nonDerivative · entry 5 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 12,500 | $22.40 | $280,000.00 |
DisclosureSEC source: 0001882909-25-000004 · form4-11062025_041101.xml · nonDerivative · entry 4 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 15,000 | $27.50 | $412,500.00 |
DisclosureSEC source: 0001882909-25-000004 · form4-11062025_041101.xml · nonDerivative · entry 3 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 17,500 | $26.88 | $470,400.00 |
DisclosureSEC source: 0001882909-25-000004 · form4-11062025_041101.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $25.25 | $252,500.00 |
DisclosureSEC source: 0001882909-25-000004 · form4-11062025_041101.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001415889-25-003822 · form4-02132025_020258.xml · derivative · entry 13 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2030-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $17.96 | $0.00 |
DisclosureSEC source: 0001415889-25-003822 · form4-02132025_020258.xml · derivative · entry 12 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001415889-25-003822 · form4-02132025_020258.xml · derivative · entry 11 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.23 | $0.00 |
DisclosureSEC source: 0001415889-25-003822 · form4-02132025_020258.xml · derivative · entry 10 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 9,244 | $25.00 | $231,100.00 |
DisclosureSEC source: 0001415889-25-003822 · form4-02132025_020258.xml · nonDerivative · entry 9 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,410 F5 · kind: This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 15,000 | $25.00 | $375,000.00 |
DisclosureSEC source: 0001415889-25-003822 · form4-02132025_020258.xml · nonDerivative · entry 8 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,654 F4 · kind: This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020 with an expiration date of January 31, 2030. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 15,000 | $15.46 | $231,900.00 |
DisclosureSEC source: 0001415889-25-003822 · form4-02132025_020258.xml · nonDerivative · entry 7 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001415889-25-003822 · form4-02132025_020258.xml · nonDerivative · entry 6 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,654 F3 · kind: This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 9, 2019 with an expiration date of May 9, 2029. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $17.96 | $179,600.00 |
DisclosureSEC source: 0001415889-25-003822 · form4-02132025_020258.xml · nonDerivative · entry 5 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001415889-25-003822 · form4-02132025_020258.xml · nonDerivative · entry 4 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,654 F2 · kind: This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 17, 2017 with an expiration date of May 17, 2027. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $17.44 | $174,400.00 |
DisclosureSEC source: 0001415889-25-003822 · form4-02132025_020258.xml · nonDerivative · entry 3 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001415889-25-003822 · form4-02132025_020258.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,654 F1 · kind: This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 19, 2016 with an expiration date of May 19, 2026. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 02:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $16.23 | $162,300.00 |
DisclosureSEC source: 0001415889-25-003822 · form4-02132025_020258.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 01:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 3,348 | $20.12 | $67,361.76 |
DisclosureSEC source: 0001415889-25-003061 · form4-02042025_080201.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,654 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 31, 2025 Filed Feb 5, 2025 01:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 26,000 | $0.00 Strike: $20.46 | $0.00 |
DisclosureSEC source: 0001415889-25-003061 · form4-02042025_080201.xml · derivative · entry 3 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2035-01-31 F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 31, 2025 Filed Feb 5, 2025 01:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003061 · form4-02042025_080201.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,002 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 01:31 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 925 | $18.94 | $17,520.24 |
DisclosureSEC source: 0001415889-25-001997 · form4-01242025_010158.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,002 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| December 26, 2024 Filed Dec 28, 2024 00:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $12.67 | $0.00 |
DisclosureSEC source: 0001415889-24-030210 · form4-12282024_121201.xml · derivative · entry 3 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.